Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

256 results about "Embryonic stem cell" patented technology

Embryonic stem cells (ES cells or ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the embryoblast, or inner cell mass (ICM) results in destruction of the blastocyst, a process which raises ethical issues, including whether or not embryos at the pre-implantation stage should have the same moral considerations as embryos in the post-implantation stage of development.

Pig chimeric embryo culture medium and application thereof in effectively improving in-vitro chimeric ability of pig embryonic stem cells

ActiveCN119351317AIncreased proliferationStrong differentiation abilityGenetically modified cellsCulture processBiotechnologyPorcine embryos
The invention discloses a pig chimeric embryo culture medium and application thereof in effectively improving the in-vitro chimeric ability of pig embryonic stem cells, and belongs to the technical field of bioengineering. According to the pig chimeric embryo culture medium disclosed by the invention, a neutral culture environment for promoting synchronous development of stem cells and embryos is created by accurately regulating and controlling growth factors, nutrient substances and other key components in the culture medium. On the basis, overexpression of anti-apoptosis factors, optimization of microinjection conditions and adoption of a laser-assisted incubation means are combined, so that the chimeric efficiency is further improved, integration of the stem cells and embryos is effectively supported, the chimeric efficiency is improved, and a reliable in-vitro tool is provided for evaluating the chimeric ability and pluripotency of the pig stem cells.
Owner:HUAZHONG AGRI UNIV

Bone organ model and construction method and application thereof

The invention provides a bone organ model as well as a construction method and application thereof, and the method comprises the following steps: arranging a biological material with a micropore array in a cell culture plate to obtain a bone organ chip; suspending the initial stem cells in a culture medium, and promoting the cells to form a spherical structure through cell aggregation or by using a non-adhesive culture surface, so as to obtain cell spheres; and culturing the cell spheres in the bone organ chip by adopting the culture medium for constructing the bone organ model to obtain the bone organ model. The skeletal organ is successfully constructed through in-vitro self-organized 3D co-culture initial stem cells including embryonic stem cells, induced pluripotent stem cells, bone marrow mesenchymal stem cells, osteoblasts, bone cells, all levels of osteogenic precursor cells, osteogenic-like cells and MC3T3-E1 cells, and the skeletal organ can become an important tool for researching and treating bone related diseases.
Owner:RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)

Method for inducing porcine embryonic stem cells to differentiate skeletal muscle cells by using complete small molecule compound

The invention belongs to the field of stem cells, and particularly relates to a method for inducing porcine embryonic stem cells to differentiate skeletal muscle cells by using a complete small molecule compound. The method comprises the following steps: S1, an induction stage: culturing the porcine embryonic stem cells in a culture medium for two days, and replacing with culture medium culture in the induction stage; s2, a differentiation stage: a differentiation stage culture medium is used for culture. The method is simple in operation process and high in efficiency, and large-scale production of the cell meat is facilitated while differentiation of the porcine embryonic stem cells into the skeletal muscle cells is achieved.
Owner:BEIJING SINOGENE BIOTECHNOLOGY CO LTD

Brain organoid containing optic vesicles generated based on h9 induction and eye-brain fusion culture method

A brain organoid containing optic vesicles generated based on H9 induction and an eye-brain fusion culture method thereof are provided. H9 embryonic stem cell induction is used to generate a brain organoid containing optic vesicles with primitive visual field. Based on an established optic vesicle brain organoid culture system, microscopic imaging is combined with specific marker antibodies related to early retinal development and photoreceptor cell maturation to structurally and functionally identify the brain organoid containing optic vesicles.
Owner:TIANJIN UNIV

Mesenchymal stem cell induced differentiation culture medium and application thereof

The invention belongs to the field of stem cell biology, and relates to pedigree specific differentiation of human pluripotent or embryonic stem cells, in particular to a mesenchymal stem cell induced differentiation culture medium and application thereof. The mesenchymal stem cell induced differentiation culture medium is used for directly inducing and differentiating human induced pluripotent stem cells / or embryonic stem cells into mesenchymal stem cells, the culture medium comprises a mesenchymal stem cell basic culture medium and an additive, and the additive comprises the following components: 2-10 [mu] M of a TGF-beta inhibitor, 2-10 [mu] M of a GSK3 beta inhibitor and 5-10 [mu] M of a Rock inhibitor. By adopting the induced differentiation culture medium provided by the invention, human induced pluripotent stem cells / or embryonic stem cells can be directly induced and differentiated into mesenchymal stem cells, and the obtained mesenchymal stem cells have the advantages of infinite sources, stable quality, high homogeneity and the like; and the human induced pluripotent stem cells / or embryonic stem cells can be directly and directionally differentiated into the mesenchymal stem cells in a relatively short time, so that the culture time is shortened, and the production cost is reduced.
Owner:HUNAN MEIBO BIOMEDICAL CO LTD

Screening method and application of human-mouse protein high homologous target antibody based on fully humanized antibody mouse

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.
Owner:CYAGEN BIOSCIENCES (SUZHOU) INC

Use of alisol-b23-acetate in prevention or treatment of hypertrophic cardiomyopathy

Disclosed in the present invention is a use of alisol-B23-acetate (AB23a) in the preparation of a drug for preventing or treating hypertrophic cardiomyopathy and diseases caused by the hypertrophic cardiomyopathy. The present invention provides for the first time a use of AB23a in the prevention or treatment of hypertrophic cardiomyopathy. According to the present invention, use of AB23a in direct in vitro treatment of cardiomyocytes derived from directed differentiation of human embryonic stem cells revealed that AB23a-based in-vitro treatment can significantly inhibit hypertrophic phenotypes of the human embryonic stem cells-cardiomyocytes; using an AB23a-containing feed to feed mice with hereditary hypertrophic cardiomyopathy caused by a gene mutation revealed that AB23a prominently relieves pathological myocardial hypertrophy of the mice and improves the cardiac function; AB23a can be used for preparing a drug for resisting hereditary hypertrophic cardiomyopathy, offering a novel way and means for treating hypertrophic cardiomyopathy; and AB23a is the main medicinal ingredient in the traditional Chinese medicinal herb-Rhizoma Alismatis, is safe to organisms, and has good clinical application prospects.
Owner:JIANGNAN UNIV

Application of exosome derived from human pluripotent stem cells in preparation of anti-hepatic inflammation drugs

The invention belongs to the technical field of medicines, and discloses application of exosomes derived from human pluripotent stem cells in preparation of anti-hepatic inflammation medicines. According to the invention, the exosome derived from the human pluripotent stem cells is applied to the preparation of the anti-hepatic inflammation medicine, especially the preparation of the anti-hepatic fibrosis anti-inflammatory medicine. The human embryonic stem cell-derived exosome can inhibit and regulate polarization of liver macrophages, inhibit inflammatory liver macrophages, up-regulate anti-inflammatory liver macrophages, reduce secretion of inflammatory factors, improve secretion of anti-inflammatory factors and inhibit liver inflammations and development thereof, has an obvious anti-inflammatory treatment effect on inflammation of liver fibrosis, and can be used for preparing medicines for treating liver fibrosis. Therefore, the progress of hepatic fibrosis can be inhibited.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

A method of preparing a liver organoid containing mesenchyme

ActiveCN119842594BCell dissociation methodsHepatocytesMesenchymeAlcohol hepatitis
The application discloses a kind of hepatic organoids containing mesenchyme induction method, belong to organoid culture technical field.The method includes the following steps: (1) human embryonic stem cell WIBR3 pretreatment;(2) utilize human embryonic stem cell WIBR3 and induce liver organoids and mesenchymal cells;(3) mesenchymal cells and liver organoid cells are co-cultured, i.e. obtain the hepatic organoids containing mesenchyme.There is beneficial effect: the application changes the culture mode and method of the hepatic organoids containing mesenchyme.The hepatic organoids containing mesenchyme induction method proposed in the application is simple, and mesenchymal cells and other liver cells have the same genetic background source, suitable for the safety evaluation of drug and other chemical substances, liver fibrosis, non-alcoholic hepatitis modeling and pharmacodynamic evaluation.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT +1

Application of Human Umbilical Cord Highly Active Mesenchymal Stem Cells

The present invention discloses an application of highly active human umbilical cord mesenchymal stem cells. HA-MSCs were isolated from human umbilical cord tissue using TeSR-E8 containing 5% CloneR and LN521-Coated culture flasks, and a technical system for HA-MSC isolation, expansion, and cryopreservation was established. Compared with conventionally cultured MSCs, the HA-MSCs prepared by the present invention have higher proliferation activity, smaller size, a higher nuclear-cytoplasmic ratio, and highly express embryonic stem cell-associated marker antigens SOX2, Nanog, and OCT4. They have the potential to differentiate into neural, myocardial, and hepato-intestinal progenitor cells derived from the three germ layers and possess excellent anti-aging activity.
Owner:AOCHEN BIOLOGICAL (YUNNAN) CO LTD

Compositions and methods for generation of bovine pluripotent embryonic stem cells

PCT designated stage expiredWO2024243481A1PeptidesUnknown materialsBiotechnologyCell culture media
The present disclosure relates to compositions and methods for growing a cell line which can be used to generate bovine pluripotent embryonic stem cells. The composition comprises a cell culture medium and at least one supplement, wherein the composition maintains pluripotency and self-renewal capacity of the cell / s. The methods employ the compositions to produce bovine embryonic stem cells which maintain their pluripotency and self-renewing capacity
Owner:UNIV OF CONNECTICUT

New use of exosome secreted by hepatocyte lineage cells differentiated via directed induction of embryonic stem cells

The present invention relates to the new use of an exosome secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and in particular relates to the use of the exosome in the preparation of a drug for treating liver diseases. The exosome is secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and the hepatocyte lineage cells are hepatic progenitor cells and / or mature hepatocyte-like cells.
Owner:GUANGXIU GAOXIN LIFE SCIENCES CO LTD HUNAN

Epitope peptide for tumor-associated antigen and use thereof

The present disclosure relates to epitope peptides for tumor-associated antigens and use thereof. The epitope peptides for tumor-associated antigens are derived from embryonic stem cells, and NUF-2. Studies have found that among embryonic stem cell-derived tumor-associated antigens selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the tumor-associated antigens KIF4A and NUF-2 expressed by embryonic stem cells (ESCs) can effectively inhibit the growth of bladder cancer, and the tumor-associated antigens CENPM, NUF-2, and IQGA3 expressed by the ESCs can strongly stimulate the immune response of specific T cells, which is manifested by stimulating peptide-specific CTL to secrete high levels of IFN-γ and inhibiting tumor growth, and the epitope peptides for tumor-associated antigens can be used in the preparation of a medicament for inhibiting the growth of tumor cells or stimulating immune cells to produce a T cell response.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Multi donor stem cell compositions and methods of making same

Disclosed are compositions, in particular, organoid compositions, derived from more than one donor cell. Further disclosed are methods of making compositions, for example, organoid compositions, that comprise a differentiated cell population derived from more than one donor cell. Donor cells may include, for example, a precursor cell such as an embryonic stem cell or other precursor cell. The disclosed methods use synchronization conditions to produce a synchronized pooled-precursor cell population, which may then be differentiated into an organoid composition. Methods of using the compositions are also disclosed.
Owner:CHILDRENS HOSPITAL MEDICAL CENT DBA CINCINNATI CHILDRENS HOSPITAL MEDICAL CENT

Method for establishing pressure stress model by utilizing hESCs induced differentiated brain organs

The invention discloses a method for establishing a pressure stress model by using a brain organ induced and differentiated by hESCs (human embryonic stem cells), which comprises the following steps: culturing human embryonic stem cells (hESCs) in a culture medium, inoculating into a U-shaped bottom 96-hole ultra-low adhesion culture plate for culturing, adding Y-27632 into the culture medium, then transferring into an embryoid (EBs) forming culture medium for culturing, and after 5 days, obtaining the pressure stress model by using the human embryonic stem cells (hESCs). The method comprises the following steps: transferring EBs into a 24-hole ultra-low adhesion culture plate containing an induction culture medium for culture, wrapping the EBs with matrigel, transferring the wrapped EBs into a 6-hole plate pretreated by the matrigel for organoid culture to form matrigel-embedded brain organs, transferring the matrigel-embedded brain organs into a mature culture medium, and putting the matrigel-embedded brain organs on a shaking table of 57-95rpm for culture to obtain the brain organs. 1-(3-chlorphenyl) piperazine hydrochloride is added into the culture medium to induce stress modeling of brain organs, and construction of the pressure stress model is completed through the scheme of 24002g / mL in 48 hours. The pressure stress model provided by the invention can be used for researching pathogenesis and drug screening of humanized stress-related neuropsychiatric diseases.
Owner:SICHUAN JUNHUI BIOTECHNOLOGY CO LTD

Preparation method of human haploid trophoblast stem cells

The invention relates to a preparation method of human haploid trophoblast stem cells, which comprises the following steps: inoculating haploid embryonic stem cells (hAG-ESCs) into a culture medium of human trophoblast stem cells (TSC), domesticating, and when TSC sample clones account for more than 50% of the proportion of all cells in the induction process, carrying out flow sorting on ITGA6 positive cells, and inoculating into the TSC culture medium again for culturing to obtain the human haploid trophoblast stem cells. After the culture, haploid trophoblast stem cells (haiTSCs) are obtained; the prepared haiTSCs are haploids, and have TSC properties. The preparation method is rapid and efficient, and the haiTSCs can be used for simulating an in-vivo disease model and have the genetic screening advantage of haploids.
Owner:NANKAI UNIV

Goat embryonic stem cell culture system and establishment method and application thereof

The invention relates to the technical field of cell biology, and particularly discloses a goat embryonic stem cell culture system, a system establishment method and application, the goat embryonic stem cell culture system takes mTeSRTM Plus as a basic culture solution, and 20 ng / mL to 25 ng / mL of leukemia inhibition factors, 1 mu M to 1.5 mu M of PD0325901, 4 mu M to 5 mu M of IWR-1, 45 mu g / mL to 50 mu g / mL of Vc, 15 ng / mL to 20 ng / mL of activin A, 1 mu M to 1.2 mu M of CGP77675 and 1.5 mu M to 2 mu M of GO6983 are added. Cell clone with clear edges is obtained through culture of a goat embryonic stem cell culture system, stable passage can be achieved, and the cell clone has the potential of being differentiated into three germ layers.
Owner:NORTHWEST A & F UNIV

Method for directionally differentiating sinus node-like cells by inducing embryonic stem cells in vitro

The invention relates to the technical field of cell differentiation, in particular to a method for in-vitro induction of directional differentiation of sinus node-like cells by embryonic stem cells, and provides application of a BMP signal selective inhibitor and a BMP signal activator in induction of in-vitro directional differentiation of sinus node-like cells by embryonic stem cells at the same time. The invention also discloses a reasonable in-vitro differentiation time window and use concentration of the inhibitor and the activator, the differentiation of hESCs to sinus node-like cells is obviously promoted by sequential and bidirectional regulation and control of a BMP signal channel, and pace-making cells with sinus node electrophysiological characteristics can be efficiently obtained in vitro. Meanwhile, the invention discloses a differentiation culture medium and a purification culture medium which are definite in substance, the generation proportion of sinus node-like cells can be remarkably increased, and the defects that in-vitro induction methods need to add various exogenous unknown proteins, and differentiation is unstable and low in efficiency are effectively overcome.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV

Suspension culture of human embryonic stem cells

This disclosure provides an improved system for culturing human embryonic stem cells. The cells are cultured in suspension so as to maximize the production capacity of the culture environment. The new culture system of this invention allows for bulk proliferation of hES cells in a more cost-effective manner, which facilitates commercial production of important products for use in human therapy.
Owner:ASTERIAS BIOTHERAPEUTICS INC

Construction method and application of human iAGM hematopoietic organoid

The invention discloses a culture medium composition for inducing human pluripotent stem cells to differentiate into human iAGM hematopoietic organoid, human embryonic stem cells are differentiated into the human iAGM hematopoietic organoid through combination and matching of different cell factors in stages, and the generated hematopoietic stem cells have high primitiveness and authenticity, so that the functionality of the hematopoietic stem cells is finally guaranteed.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

Precursory regulatory cytotrophoblast cells and uses thereof

To provide stem cell therapies for treating (curing) a variety of diseases or conditions, as an alternative to overcome certain shortcomings of existing embryonic stem cells and iPS cells.SOLUTION: Provided herein are: precursory regulatory cytotrophoblast cells produced in vitro and expressing specific cell surface proteins and combinations thereof; compositions thereof; and methods of treating disorders (e.g., cancers, inflammations, or autoimmune diseases) or conditions (e.g., skin conditions) by using the cells and compositions.SELECTED DRAWING: None
Owner:ACCELERATED BIOSCIENCES CORP

Methods and compositions for in vitro embryonic development from pluripotent stem cells

Disclosed herein are methods, compositions, and culture media for generating synthetic embryos in vitro from mammalian pluripotent stem cells, such as pluripotent embryonic stem cells. In some embodiments, the methods can include co-culturing wild-type mammalian pluripotent stem cells with modified mammalian pluripotent stem cells that include one or more genes encoding transcription factors that can drive the generation of extraembryonic or extraembryonic-like cells (e.g., GATA6, SOX17, GATA3, and / or TFAP2C genes) in a culture medium under conditions that allow the pluripotent stem cells to self-organize into post-implantation embryonic structures. In some embodiments, the pluripotent embryonic stem cells are human pluripotent embryonic stem cells, and the generated synthetic embryo is a human embryo.
Owner:CALIFORNIA INST OF TECH +1

Methods and systems for converting precursor cells into intestinal tissues through directed differentiation

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

Application of Alismatol B Acetate in the Prevention or Treatment of Hypertrophic Cardiomyopathy

This invention discloses the application of alismazone B acetate in the preparation of drugs for the prevention or treatment of hypertrophic cardiomyopathy and its related symptoms. This invention is the first to propose the use of alismazone B acetate (AB23a) for the prevention or treatment of hypertrophic cardiomyopathy. The invention utilizes AB23a to directly treat cardiomyocytes obtained from directed differentiation of human embryonic stem cells in vitro, finding that AB23a treatment significantly inhibits the hypertrophic phenotype of human embryonic stem cell-cardiomyocytes. Feeding mice with hereditary hypertrophic cardiomyopathy caused by gene mutations to a diet containing AB23a showed that AB23a significantly alleviated pathological myocardial hypertrophy and improved cardiac function in mice. AB23a can be used to prepare drugs against hereditary hypertrophic cardiomyopathy, providing a new approach and method for treating hypertrophic cardiomyopathy. AB23a is the most important medicinal component of the traditional Chinese medicine Alisma plantago-aquatica, is safe for organisms, and has good clinical application prospects.
Owner:JIANGNAN UNIV

A human umbilical cord highly active mesenchymal stem cell and its preparation method and application

The present invention discloses a human umbilical cord highly active mesenchymal stem cell and a preparation method and application thereof. HA-MSCs are separated from human umbilical cord tissue using TeSR-E8 containing 5% CloneR and LN521-Coated culture bottles, and a HA-MSC separation, amplification, and cryopreservation technical system is established. Compared with other separation methods, it is simpler and easier, and the time from the tissue being removed from the body to entering the incubator is shorter, which largely maintains the cell activity. The established primary culture method enables the primitive cells or cells with strong pluripotency in the tissue to be sorted out from the primary generation, and can be stably passaged and preserved, providing a prerequisite for subsequent amplification. Compared with conventionally cultured MSCs, the HA-MSCs prepared by the present invention have higher proliferation activity, smaller volume, higher nuclear-cytoplasmic ratio, and highly express embryonic stem cell-related marker antigens SOX2, Nanog, and OCT4, and have the potential to differentiate into neural, myocardial, and hepato-intestinal progenitor cells derived from the three germ layers.
Owner:AOCHEN BIOLOGICAL (YUNNAN) CO LTD

Spot universal CFR64-T cell prepared based on CRISPR / Cas9, and preparation method and application thereof

The invention provides a spot universal CFR64-T cell prepared on the basis of CRISPR / Cas9 as well as a preparation method and application thereof. The CFR64-T cell is obtained by induced differentiation of recombinant human embryonic stem cells; in the recombinant human embryonic stem cell, a coding sequence of a CFR64 molecule is knocked into a TRAC site of the human embryonic stem cell at a fixed point through a CRISPR / Cas9 editing system; the CFR64 molecule comprises an antigen binding structural domain, a transmembrane structural domain and an intracellular costimulatory signal structural domain, the antigen binding domain is a human Fc gamma receptor extracellular domain, and the amino acid sequence of the antigen binding domain is shown in SEQ ID NO: 1. The CRISPR / Cas9 technology is adopted, gene integration sites are controllable and free of oncogene mutation risks, TCR genes are knocked out, the immunological rejection risk of universal CFR64-T cells to hosts is reduced, and meanwhile gene expression is more stable.
Owner:SHENZHEN IN VIVO BIOMEDICINE TECH LTD

Photoreceptor rescue cell (PRC) compositions and methods of treating ocular conditions

The present invention provides populations of photoreceptor rescue cells (PRCs) having a unique profile of markers and resulting from in vitro differentiation of early progenitor cells, including pluripotent stem cells and embryonic stem cells (ESCs). Also provided are methods of generating populations of photoreceptor-rescuing cells and methods of using them to treat ocular conditions.
Owner:ADVANCED CELL TECH INC

Thermostable FGF10 Polypeptide or Fragment Thereof and Use Thereof

The invention relates to a thermostable FGF10 polypeptide possessing FGF10 activity and having or comprising at least 85% sequence identity to SEQ ID NO:3 that has or comprises an amino acid sequence from Ser69 to Ser208 of SEQ ID NO:1, or to SEQ ID NO:5 that has or comprises an amino acid sequence from Leu40 to Ser208 of SEQ ID NO:1, or the fragments thereof, comprising at least an amino acid substitution L152F. Preferably, any of amino acid substitutions V123I, Q175E, and N181D can be further included. The invention further discloses the use of subjected thermostable FGF10 polypeptides in regenerative medicine or other related medical applications or cosmetics. Further, it discloses a culture medium comprising subjected thermostable FGF10 polypeptides suitable for proliferation and differentiation of the human embryonic stem cells or formation and differentiation of spheroids and organoids.
Owner:CONTIPRO AS

Methods and compositions for treating cancers

To provide a novel therapeutic strategy for treating cancers expressing embryonic antigens.SOLUTION: The inventors have developed a metastatic 4T1 breast tumor model in BALB / c mice. The inventors have showed that vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher antitumor response against a breast cancer and inhibits metastasis development. The inventors have demonstrated that these responses are only achieved by the addition of valproic acid in a therapeutic regimen compared to the use of ESC or iPSC alone. Thus, the inventors provide a novel therapeutic strategy for treating cancers expressing embryonic antigens. The present invention therefore relates to a method for treating a subject suffering from cancer, comprising the steps of administering to the subject simultaneously, separately or sequentially a therapeutic amount of i) a population of pluripotent cells and ii) a compound selected from the group that activates MHC expression as a combined preparation.SELECTED DRAWING: None
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3